Figure 2

Survival curves in patients with very early HCC treated with different modalities. The difference in survival according to treatment is not statistically significant (p = 0.06) [OLTx median survival 90 months; resection 86 months (CI 16–156), RFTA and PEI 65 months (CI 54–76), TACE 60 months (CI 37–83), BSC 15 months (CI 6–43)]. (OLTx: orthotopic liver transplantation; RFTA: radiofrequency-mediated thermal ablation; PEI: percutaneous ethanol injection; TACE: transcatheter arterial chemoembolization; BSC: best supportive care).